Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice.

This article discusses the effectiveness of secukinumab (SEC) for the treatment of erythrodermic psoriasis (EP), a rare and severe form of psoriasis. The study was conducted in daily practice conditions and included 16 patients from Portuguese and Spanish hospitals. The results showed that SEC was effective and safe for treating EP, with a significant improvement observed at 3 months and sustained effectiveness over a longer follow-up period. This study represents the largest series of EP patients treated with SEC and provides evidence for SEC as a potential treatment alternative for this severe clinical form of psoriasis. [Extracted from the article]